美国食品药品监督管理局（FDA）已正式授予Encorafenib传统批准，用于治疗携带BRAF V600E突变的转移性结直肠癌患者。这一决定为特定基因突变类型的晚期结直肠癌患者提供了新的靶向治疗选择。
美国食品药品监督管理局（FDA）已正式授予Encorafenib传统批准，用于治疗携带BRAF V600E突变的转移性结直肠癌患者。这一决定为特定基因突变类型的晚期结直肠癌患者提供了新的靶向治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.